Latest News

(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. Each of these treatment approaches has utilized an immunotherapy backbone with immune checkpoint inhibition. In a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting, Dr. Sautes-Fridman discussed the potential for targeting […]

(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. In spite of all these changes, more changes are coming. In a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting, Dr. Vano discussed biomarker-driven trials.

(UroToday.com) At the Southeastern Section of the AUA 2021 virtual meeting’s prostate cancer session, Dr. Todd Morgan discussed new imaging techniques in prostate cancer, with a focus on understanding indications and techniques for imaging in patients with suspected metastatic prostate cancer and comparing the performance of current and future molecular imaging modalities for metastatic detection.

(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. In spite of all these changes, more changes are coming. In a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting, Dr. Hammers discussed future therapeutic approaches in RCC.

(UroToday.com) Incidental discovery of renal masses has increased with more utilization of cross-sectional imaging, leading to more partial and radical nephrectomies. However, contrast-enhanced imaging is unreliable in differentiating between benign oncocytoma and malignancy kidney masses. The Aorta-Lesion-Attenuation-Difference (ALAD) and Peak Early-phase Enhancement Ratio (PEER) are two imaging-based calculations that may be used to differentiate oncocytoma versus malignancy.1 […]

(UroToday.com) Prostate cancer remains the most commonly diagnosed malignancy for men in the United States. Genetic inheritance does portend significant risk in developing aggressive prostate cancer, yet there is limited understanding of whether germline alterations play a significant role in localized disease for men on active surveillance. At the Southeastern Section of the AUA 2021 virtual […]

Geographic and temporal variation in positive surgical margins (PSM) for prostate cancer after radical prostatectomy (RP) has been observed. However, it is unclear how much of this variation could be attributed to patient, surgeon, institution, or socioeconomic-related factors and the impact of PSM on death among localized prostate cancer patients.

177Lu-PSMA-617 radioligand-therapy is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to patients with metastatic hormone-sensitive prostate cancer (mHSPC) with PSMA expression.

Intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) has an incidence of approximately 20-50%. Studies to date have been composed of mixed treatment cohorts – open, laparoscopic, and robotic.

(UroToday.com) African American men have an increased risk of diagnosis and mortality for prostate cancer, but it remains unclear if this is due to cancer biology, anterior tumor location, or access to novel diagnostic tools for identifying localized cancer. MRI fusion biopsy represents the new standard of care for accurate diagnosis of localized prostate cancer but […]